- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02225561
SNPeCPR In Cardiac Arrest REsuscitation (SICARE)
SNPeCPR Pour la prIse en Charge Des Arrêts CaRdiaques Extrahospitaliers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES The objective of this study is to demonstrate the superiority of Sodium nitroprusside enhanced cardiopulmonary resuscitation (SNPeCPR) on optimized standard cardiopulmonary resuscitation.
SNPeCPR includes two components:
- a mechanical component: cardiopulmonary resuscitation with automated mechanical external chest compression and an impedance threshold device
- a pharmacological component: sodium nitroprusside, an effective arterial vasodilator that decreasing vascular resistance, facilitates flow elevation in vital organs.
1.1. Main Objective : Assess the interests of the administration of sodium nitroprusside during enhanced cardiopulmonary resuscitation.
1.2. Secondary Objectives : To evaluate the effect of sodium nitroprusside on various parameters before and after the return of spontaneous circulation.
1.3. Outcome Measures : In this declaration, all the criterions measures before ROSC have been note as t=0 minute.
For the elements were the timeframe is a variable, ICU and hospital discharge, they have been declare at 1 and 2 weeks respectively.
- NAME AND DESCRIPTION OF THE INVESTIGATIONAL DRUG Sodium nitroprusside (SNP) is a potent vasodilator that we will use in cardiac arrest to optimize vital organs perfusion. The purpose of CPR is to provide oxygenated blood to vital organs that are most susceptible to ischemic insult (brain and heart). Since the mechanical combination (cardiopulmonary resuscitation with automated mechanical external chest compression and an impedance threshold device) provides excellent perfusion pressure, the flow should be optimized pharmacological with vasodilation. The SNP reduces arterial vasoconstriction and enhances microcirculation. Furthermore, SNP significantly reduces vascular resistance and decreases cardiac ejection afterload. Therefore, SNPeCPR can significantly increase the flow of blood and optimize carotid and coronary flow.
PROCEDURE During cardiac arrest resuscitation, patients will be included in the study after the investigator has verified the inclusion and non-inclusion criterion. A sealed box containing SNP or the placebo will then be open in the increasing numbers of randomization list.
Whatever the allocated treatment (nitroprusside or Placebo [5% glucose solution]), cardiopulmonary resuscitation protocol will be realize as recommended by the 2010 European Resuscitation Council and described as follows:
- cardiopulmonary resuscitation will be performed continuously without posing for control pulse until the first defibrillation attempt. As soon as possible manual CPR will be replace by automated mechanical external chest compression (LUCAS® - Lund University Cardiopulmonary Assist System) and an impedance threshold device (ResQPOD®).
- placement of a peripheral intravenous (IV) or intraosseous (IO) line. This placement will be privileged to intubation,
- when the peripheral intravenous or intraosseous line is set, 1.96 mg sodium nitroprusside (SNP) / placebo will be injected, followed by injection of 10 ml saline for intravenous flush (t = 0 minutes).
- 1 mg of epinephrine will be injected at t = 2 minutes,
- an external electric shock (EEC) will be realized at t = 3 minutes when the electric heart type allows it (ventricular fibrillation or ventricular tachycardia),
- 0.98 mg sodium nitroprusside / placebo will be injected at t = 4 minutes, followed by an injection of 10 ml of saline for intravenous flush.
- 1 mg adrenaline will be injected at t = 7 minutes, the injection will be repeated every 5 minutes until return of spontaneous circulation or ending of the resuscitation decided by the emergency physician.
- an external electric shock (EEC) will be realized at t = 6 minutes when the electric heart type allows, then external shock will be repeated every 3 minutes until return of spontaneous circulation or ending of the resuscitation decided by the emergency physician.
During that resuscitation the following parameters will be collected:
- The type of cardiac arrest (place of cardiac arrest [home, public place, stadium …], cardiac arrest before a witness or prompt rescue team, cardiac massage by the witness or prompt rescue team, durations between collapse and the start of resuscitation, non-specialized / specialized resuscitation, defibrillation shock by the witness or prompt rescue team), ETCO2, blood pressure and SpO2.
- the initial electrical rhythm (defined by ECG) by the mobile intensive care unit (MICI) and ECG 5 minutes after return of spontaneous circulation.
- arterial blood gas lactate
- troponin (24 hours after ROSC)
- liver function (24 hours after ROSC)
- creatinine (24 hours after ROSC)
- echocardiography (4 and 24 hours after ROSC)
EXPECTED DURATION OF PARTICIPATION OF PEOPLE AND DESCRIPTION OF THE TIMING AND DURATION OF THE RESEARCH.
Duration of intervention: 4 minutes Inclusion time: 30 months duration of participation (+ monitoring treatment): 6 months Total duration of the study: 3 years
- RANDOMIZATION Randomization will be realized by block and will be stratified by center. The boxes are numbered and contain drugs specified by the randomization arm. Randomization will be done by assigning at each inclusion a box taken in order of increasing numbers of the randomization list. The randomization list will be established under the responsibility of the clinical research unit.
- MONITORING COMMITTEE A monitoring committee will conduct an interim analysis after the inclusion of 50% and 75% of patients and will decide to stop or continue the study.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75010
- SMUR - Hôpital Lariboisière
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with out of hospital cardiac arrest
- Age> 18 years and <75 years
- Initial Rhythm: Ventricular fibrillation or ventricular tachycardia or pulseless electrical activity
Exclusion Criteria:
out of hospital cardiac arrest of non-cardiac origin:
- trauma
- anoxic, including drowning
- hemorrhage,
- overdose (drugs),
- drug,
- electric
- Do Not Resuscitate Order,
- obvious signs of clinical death (decomposition, cadaveric rigidity, decapitation)
- recent sternotomy (<6 months or recent scar)
Contraindications related to sodium nitroprusside
- Women of childbearing age (between 18 and 55 years)
- Other contra-indications will usually not known during resuscitation in case of presence of a relative rescue team must be searched: Hypothyroidism, Sulfuryl transferase deficiency (rhodanese Lang) currently recognized in patients with Leber optic atrophy, tobacco amblyopia or severe hepatic impairment.
- Obesity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention arm
Pharmaco- mechanical optimization
|
Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt. As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:
|
ACTIVE_COMPARATOR: Mechanical optimization only
|
Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council .
It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of return of spontaneous circulation (ROSC)
Time Frame: at 5 minutes
|
Rate of return of spontaneous circulation (ROSC) defined as a central pulse (carotid or femoral) palpable for more than 5 minutes
|
at 5 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ETCO2
Time Frame: at 0, 5 and 60 minutes
|
ETCO2 (before ROSC, 5 and 60 min after ROSC)
|
at 0, 5 and 60 minutes
|
Blood pressure
Time Frame: at 5 and 60 min
|
at 5 and 60 min after ROSC
|
at 5 and 60 min
|
ECG
Time Frame: at 0, 5 and 60 minutes
|
ECG (before ROSC, 5 min after ROSC)
|
at 0, 5 and 60 minutes
|
SpO2
Time Frame: at 0, 5 and 60 minutes
|
SpO2 (before ROSC, 5 and 60 min after ROSC)
|
at 0, 5 and 60 minutes
|
Arterial blood gases with lactate
Time Frame: at 0 and 5 minutes; 1, 4 and 24 hours
|
arterial blood gases with lactate (before ROSC, 5 min, 1, 4 and 24 hours after ROSC)
|
at 0 and 5 minutes; 1, 4 and 24 hours
|
Troponin
Time Frame: at 24 hours
|
troponin (24 hours after ROSC)
|
at 24 hours
|
Liver function
Time Frame: at 24 hours
|
liver function (24 hours after ROSC)
|
at 24 hours
|
Creatinine
Time Frame: at 24 hours
|
creatinine (24 hours after ROSC)
|
at 24 hours
|
Echocardiography
Time Frame: at 4 and 24 hours
|
echocardiography (4 and 24 hours after ROSC)
|
at 4 and 24 hours
|
Survival
Time Frame: 1, 4 and 24 hours, 1 week, 2 weeks, 1 and 6 months
|
survival (1, 4 and 24 hours after ROSC, ICU and hospital discharge, 1 and 6 months)
|
1, 4 and 24 hours, 1 week, 2 weeks, 1 and 6 months
|
Neurological score
Time Frame: 1 week, 2 weeks, 1 and 6 months
|
neurological score (ICU and hospital discharge, 1 and 6 months)
|
1 week, 2 weeks, 1 and 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Patrick PLAISANCE, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
General Publications
- Schultz J, Segal N, Kolbeck J, Caldwell E, Thorsgard M, McKnite S, Aufderheide TP, Lurie KG, Yannopoulos D. Sodium nitroprusside enhanced cardiopulmonary resuscitation prevents post-resuscitation left ventricular dysfunction and improves 24-hour survival and neurological function in a porcine model of prolonged untreated ventricular fibrillation. Resuscitation. 2011 Dec;82 Suppl 2(0 2):S35-40. doi: 10.1016/S0300-9572(11)70149-6.
- Schultz J, Segal N, Kolbeck J, McKnite S, Caldwell E, Yannopoulos D. Sodium nitroprusside enhanced cardiopulmonary resuscitation (SNPeCPR) improves vital organ perfusion pressures and carotid blood flow in a porcine model of cardiac arrest. Resuscitation. 2012 Mar;83(3):374-7. doi: 10.1016/j.resuscitation.2011.07.038. Epub 2011 Aug 22.
- Schultz JC, Segal N, Caldwell E, Kolbeck J, McKnite S, Lebedoff N, Zviman M, Aufderheide TP, Yannopoulos D. Sodium nitroprusside-enhanced cardiopulmonary resuscitation improves resuscitation rates after prolonged untreated cardiac arrest in two porcine models. Crit Care Med. 2011 Dec;39(12):2705-10. doi: 10.1097/CCM.0b013e31822668ba.
- Yannopoulos D, Matsuura T, Schultz J, Rudser K, Halperin HR, Lurie KG. Sodium nitroprusside enhanced cardiopulmonary resuscitation improves survival with good neurological function in a porcine model of prolonged cardiac arrest. Crit Care Med. 2011 Jun;39(6):1269-74. doi: 10.1097/CCM.0b013e31820ed8a6.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P130946
- 2014-002010-24 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiopulmonary Arrest
-
Shaare Zedek Medical CenterUnknown
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Hospital Universitari Joan XXIII de Tarragona.Not yet recruitingCardiopulmonary Arrest With Successful Resuscitation | Cardiorespiratory ArrestSpain
-
Brigham and Women's HospitalMassachusetts General Hospital; American Heart AssociationRecruitingCardiopulmonary Arrest With Successful Resuscitation | Educational ProblemsUnited States
-
Zonguldak Bulent Ecevit UniversityNurten TaşdemirCompletedCardiopulmonary Arrest With Successful Resuscitation | Education, NursingTurkey
-
Cristina GenzorHospital Miguel ServetUnknownCardiopulmonary Arrest With Successful Resuscitation | Child, OnlySpain
-
Fundacio d'Investigacio en Atencio Primaria Jordi...CompletedCardiopulmonary Arrest With Successful ResuscitationSpain
-
Pontificia Universidade Católica do Rio Grande...CompletedCardiopulmonary Arrest With Successful Resuscitation
-
Baqiyatallah Medical Sciences UniversityShahid Beheshti University; Tehran University of Medical Sciences; East Carolina...CompletedCardiopulmonary Resuscitation | Cardiopulmonary Arrest
-
Medical University of ViennaCompletedCardiopulmonary Arrest With Successful Resuscitation | Cardiac Arrest | Cardiopulmonary Arrest | Cardiac Arrest, Out-Of-HospitalAustria
-
Seoul National University HospitalCompletedCardiopulmonary Resuscitation | Education | Cardiopulmonary ArrestKorea, Republic of
Clinical Trials on pharmaco- mechanical optimization
-
Assiut UniversityRecruitingAcute Limb IschemiaEgypt
-
University Hospital, Gentofte, CopenhagenRigshospitalet, Denmark; Lund University HospitalUnknownHeart Failure | Ischemic CardiomyopathyDenmark, Sweden
-
MicroPort CRMCompleted
-
MicroPort CRMSorin CRMUnknownHeart Failure NYHA Class III and Ambulatory IVUnited States, Spain, United Kingdom, Germany, Italy, Australia, Netherlands, Portugal, France, Austria, Switzerland, Slovenia
-
Fondation Ophtalmologique Adolphe de RothschildTerminatedOcclusion or Malformation of a Cerebral VesselFrance
-
University Hospital DubravaCompletedHypotension During SurgeryCroatia
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Infections | Pregnancy Related | Pre-Exposure ProphylaxisKenya
-
Claude Bernard UniversityCompleted
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH); amfAR, The Foundation for AIDS ResearchRecruiting
-
Jessa HospitalCompletedQuality of Life | Pacemaker Ddd Permanent | Atrial DysfunctionBelgium